fingolimod hydrochloride has been researched along with Cardiovascular Diseases in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Callegaro, D; Sato, DK | 1 |
| Arruda, CC; Arruda, WO; Brooks, JB; Damasceno, A; Damasceno, CA; de Morais, MM; Finkelsztejn, A; Finkelsztejn, J; Fragoso, YD; Gama, PD; Giacomo, MC; Gomes, S; Goncalves, MV; Matta, AP; Oliveira, EM; Ribeiro, Y; Sato, HK; Tauil, CB | 1 |
| Hla, T; Proia, RL | 1 |
| Baldock, L; Datt, J; Pull, E; Webber, B | 1 |
| D'Crus, A; Enjeti, AK; Melville, K; Rowlings, P; Verrills, NM | 1 |
| Airas, L; Hovi, A | 1 |
| Limmroth, V; Meissner, A | 1 |
3 review(s) available for fingolimod hydrochloride and Cardiovascular Diseases
| Article | Year |
|---|---|
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.
Topics: Acute Lung Injury; Anemia, Sickle Cell; Animals; Autoimmune Diseases; Cardiovascular Diseases; Cell Physiological Phenomena; Disease Models, Animal; Fingolimod Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Influenza, Human; Lysophospholipids; Membrane Lipids; Mice; Multiple Sclerosis; Neoplasms; Neovascularization, Physiologic; Neurogenesis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2015 |
A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Fingolimod Hydrochloride; Humans; Infections; Leukemia, Myeloid, Acute; Observational Studies as Topic | 2016 |
Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting | 2016 |
6 other study(ies) available for fingolimod hydrochloride and Cardiovascular Diseases
| Article | Year |
|---|---|
Fingolimod. Check cardiovascular status again on treatment resumption.
Topics: Cardiovascular Diseases; Death, Sudden; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Propylene Glycols; Sphingosine | 2014 |
Oral fingolimod to treat multiple sclerosis: see your cardiologist first.
Topics: Cardiovascular Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
Topics: Adult; Aged; Bradycardia; Cardiovascular Diseases; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Time Factors; Young Adult | 2014 |
The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Monitoring, Physiologic; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome; United Kingdom | 2016 |
Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
Topics: Adult; Cardiovascular Diseases; Cohort Studies; Female; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Lipids; Male; Multiple Sclerosis, Relapsing-Remitting; Risk Factors; Treatment Outcome | 2016 |
Fingolimod: cardiovascular deaths.
Topics: Cardiovascular Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |